Naploy Corp. (NPLY) intrinsic value & 10-year financials

Naploy Corp. (NPLY) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue reached to $8.0K, with an average return on invested capital of -289.4%.

Graham intrinsic value
—
Revenue (FY2025)
$8.0K
ROIC (10-yr avg)
-289.4%
Free cash flow (FY2025)
—

NPLY 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $8.0K -$20.7K -$0.01 — -260.6% 1420.2%
FY2024 $0 -$20.3K -$0.01 — — -1999.1%
FY2023 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Naploy Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

Naploy Corp. has historically struggled to out-earn its cost of capital, averaging just -2.9% ROIC.

Naploy Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Naploy Corp. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

NPLY stock: frequently asked questions

What is the intrinsic value of Naploy Corp. (NPLY) stock?

Graham's formula only works with positive earnings. Naploy Corp. reported diluted EPS of -$0.01 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

What is NPLY's return on invested capital?

Average ROIC over the last 3 fiscal years was -289.4%, and average return on equity was -289.4%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this NPLY data come from?

From Naploy Corp.'s annual 10-K filings on SEC EDGAR, most recently filed May 21, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar health services stocks